

Mild Synthesis of Substituted 1,2,5-Oxadiazoles Using 1,1'-Carbonyldiimidazole as a Dehydrating Agent

Andrew J. Neel*, Ralph Zhao

Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States

Supporting Information

General Information	S2
Synthesis of Substrates	S3
Synthesis of Furazans	S9
Furazan Derivatization	S15
Chiral SFC Trace of 2o	S20
DSC Data	S21
Cyano-oxime NMR Spectra	S25
Furazan NMR Spectra	S43


General Information

Unless otherwise noted, all reagents were purchased from commercial suppliers and used without further purification. Unless otherwise noted, all reactions were conducted in standard glassware without special precaution to exclude air or moisture. Thin layer chromatography (TLC) analysis of reaction mixtures was performed using Merck KGaA silica gel 60 F₂₅₄ TLC plates and visualized using UV light and/or potassium permanganate solution. Column chromatography was conducted using a Teledyne Isco CombiFlash system equipped with disposable RediSep R_f silica columns. Nuclear magnetic resonance (NMR) spectra were recorded using Bruker 500 and 400 MHz spectrometers. ¹H and ¹³C chemical shifts are reported in parts per million (ppm) downfield of tetramethylsilane (TMS) and referenced to residual solvent peak (CHCl₃; δ H = 7.26 ppm and δ C = 77.0 ppm, DMSO; δ H = 2.50 and δ C = 39.5 ppm). Multiplicities are reported using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, app d = apparent double, app t = apparent triplet, m = multiplet, br = broad resonance. Solvent abbreviations are reported as follows: EtOAc = ethyl acetate, hexs = hexanes, DCM = dichloromethane, MeOH = methanol, THF = tetrahydrofuran, DMF = N,N-dimethylformamide, Et₃N = trimethylamine. Ultra-performance liquid chromatography (UPLC) analysis was conducted using an Agilent 1290 Infinity II using a Waters Acquity C18 UPLC column (2.1 x 100 mm, 1.7 μ m). Cyano-oxime **3m** has been previously reported.¹

Note: Although there were no incidents during the preparation of this manuscript, due to the energetic nature of the compounds described herein, caution should be exercised during their handling and manipulation. It is recommended that cyano-oximes, *bis*-oximes and furazans not be ground (e.g. in a mortar and pestle) as they may be shock-sensitive and that care be taken to avoid contact between these compounds and metal objects (e.g. spatulas during weighing). It is recommended that reactions be conducted behind a blast shield and that sufficient venting is provided for larger-scale CDI-induced cyclodehydration reactions due to the concomitant off-gassing.

Synthesis of Substrates


Scheme S1. Synthesis of cyano-oximes



General Procedure A: A 100-mL round-bottomed flask equipped with a magnetic stir bar was charged with the nitrile substrate (1.0 eq) and MeCN (0.2 M). To the stirred mixture was added concentrated HCl (10.0 eq). In a separate 1 dram vial, sodium nitrite (2.2 eq) was dissolved in H₂O (7 M with respect to sodium nitrite). The resulting aqueous solution was added dropwise to the stirred reaction mixture at room temperature and stirred for 2-12 h. Upon complete consumption of the starting material, as judged by UPLC analysis, the reaction mixture was diluted with H₂O and transferred to a separatory funnel. The aqueous layer was extracted with EtOAc (x3). The combined organics were washed with brine (x1), dried (Na₂SO₄) and concentrated *in vacuo*. The crude residue was purified by column chromatography on silica gel using EtOAc/Hexs as eluent.


General Procedure B: A 100-mL round-bottomed flask equipped with a magnetic stir bar was charged with the nitrile substrate (1.0 eq) and DMF (0.2 M). The atmosphere was purged with N₂ and the mixture was cooled to 0 °C using an ice water bath. To the stirred mixture was added potassium *tert*-butoxide (1.6 M in THF, 1.2 eq), resulting in a color change from colorless to yellow. After 5 min, *tert*-butyl nitrite (2.0 eq) was added, resulting in a deep red color, and the reaction mixture was allowed to warm to room temperature. Upon complete consumption of the starting material, as judged by UPLC analysis (typically 30-60 min), 1 N HCl was added until the red color faded and the mixture was transferred to a separatory funnel. The aqueous layer was extracted with EtOAc (x2). The combined organics were washed with H₂O (x3), brine (x1), dried (Na₂SO₄) and concentrated *in vacuo*. The crude residue was purified by column chromatography on silica gel using EtOAc/Hexs as eluent.

N-hydroxy-2-oxo-2-(phenylamino)acetimidoyl cyanide (3a)




Subjection of **S1a** (1.97 g, 12.3 mmol) to General Procedure A gave the title compound (1.7 g, 8.99 mmol, 73 % yield) as a yellow solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 14.63 (s, 1H), 10.41 (s, 1H), 7.69 (d, *J* = 8.0 Hz, 2H), 7.36 (app t, *J* = 7.7 Hz, 2H), 7.15 (t, *J* = 7.3 Hz, 1H). **¹³C NMR** (126 MHz, DMSO) δ 157.3, 138.0, 129.1, 129.1, 125.0, 121.3, 109.3. **HRMS** (ESI) found [M+H]⁺ 190.0619, C₉H₈N₃O₂ requires 190.0616.

(E)-N-hydroxy-2-oxo-2-(pyrrolidin-1-yl)acetimidoyl cyanide (3b)




Subjection of **S1b** (1.0 g, 7.24 mmol) to General Procedure A gave the title compound (1.18 g, 7.06 mmol, 98 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 14.28 (s, 1H), 3.62 (t, *J* = 6.5 Hz, 2H), 3.43 (t, *J* = 6.7 Hz, 2H), 1.87-1.81 (m, 4H). **¹³C NMR** (126 MHz, DMSO) δ 157.5, 129.5, 109.7, 48.8, 47.4, 26.2, 23.8. **HRMS** (ESI) found [M+H]⁺ 168.0772, C₇H₁₀N₃O₂ requires 168.0773.

(E)-N-hydroxy-2-oxo-2-(piperidin-1-yl)acetimidoyl cyanide (3c)



Subjection of **S1c** (1.0 g, 6.57 mmol) to General Procedure A gave the title compound (1.10 g, 6.07 mmol, 92 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 14.20 (s, 1H), 3.56-3.50 (m, 4H), 1.65-1.60 (m, 2H), 1.55-1.51 (m, 4H). **¹³C NMR** (126 MHz, DMSO) δ 157.8, 127.5, 109.8, 48.1, 43.7, 26.5, 25.6, 24.2. **HRMS** (ESI) found [M+H]⁺ 182.0935, C₈H₁₂N₃O₂ requires 182.0930.


(E)-N-hydroxy-2-morpholino-2-oxoacetimidoyl cyanide (3d)



Subjection of **S1d** (1.0 g, 6.49 mmol) to General Procedure A gave the title compound (1.12 g, 6.13 mmol, 94 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 14.29 (s, 1H), 3.64 – 3.54


(m, 8H). ^{13}C NMR (126 MHz, DMSO) δ 158.2, 127.4, 109.77, 66.5, 66.2, 47.6, 43.2. HRMS (ESI) found $[\text{M}+\text{H}]^+$ 184.0718, $\text{C}_7\text{H}_{10}\text{N}_3\text{O}_3$ requires 184.0722.

(E)-2-((4-chlorophenyl)amino)-N-hydroxy-2-oxoacetimidoyl cyanide (3e)




Subjection of **S1e** (2.0 g, 10.28 mmol) to General Procedure A gave the title compound (2.15 g, 9.61 mmol, 94 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 14.66 (s, 1H), 10.55 (s, 1H), 7.74 (d, J = 8.5 Hz, 2H), 7.42 (d, J = 8.6 Hz, 2H). ^{13}C NMR (126 MHz, DMSO) δ 157.4, 137.0, 129.1, 129.0, 128.7, 122.8, 109.3. HRMS (ESI) found $[\text{M}+\text{H}]^+$ 222.0078, $\text{C}_9\text{H}_7\text{ClN}_3\text{O}_2$ requires 222.0071.

(E)-2-((4-fluorophenyl)amino)-N-hydroxy-2-oxoacetimidoyl cyanide (3f)




Subjection of **S1f** (0.880 g, 4.94 mmol) to General Procedure A gave the title compound (0.453 g, 2.19 mmol, 44 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (2:1 to 1:1). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 14.64 (s, 1H), 10.48 (s, 1H), 7.71 (m, 2H), 7.20 (app t, J = 8.7 Hz, 2H). ^{13}C NMR (126 MHz, DMSO) δ 159.2 (d, J = 241.7 Hz), 157.3, 134.4 (d, J = 2.7 Hz), 129.0, 123.3 (d, J = 8.1 Hz), 115.8 (d, J = 22.4 Hz), 109.3. HRMS (ESI) found $[\text{M}+\text{H}]^+$ 208.0528, $\text{C}_9\text{H}_7\text{FN}_3\text{O}_2$ requires 208.0522.

(E)-N-hydroxy-2-oxo-2-((4-(trifluoromethyl)phenyl)amino)acetimidoyl cyanide (3g)




Subjection of **S1g** (1.0 g, 4.38 mmol) to General Procedure A gave the title compound (1.05 g, 4.08 mmol, 93 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (3:1 to 1:1). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 14.74 (s, 1H), 10.76 (s, 1H), 7.94 (d, J = 8.3 Hz, 2H), 7.73 (d, J = 8.3 Hz, 2H). ^{13}C NMR (126 MHz, DMSO) δ 157.9, 141.8, 129.0, 126.5 (q, J = 3.8 Hz), 124.9 (q, J = 32.1 Hz), 124.7 (q, J = 272.0 Hz), 121.1, 109.2. HRMS (ESI) found $[\text{M}+\text{H}]^+$ 258.0490, $\text{C}_{10}\text{H}_7\text{F}_3\text{N}_3\text{O}_2$ requires 258.0490.

(E)-N-hydroxy-2-((4-methoxyphenyl)amino)-2-oxoacetimidoyl cyanide (3h)




Subjection of **S1h** (1.0 g, 5.26 mmol) to General Procedure A gave the title compound (0.700 g, 3.19 mmol, 61 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 14.56 (s, 1H), 10.30 (s, 1H), 7.59 (d, *J* = 8.9 Hz, 2H), 6.93 (d, *J* = 8.9 Hz, 2H), 3.74 (s, 3H). **¹³C NMR** (126 MHz, DMSO) δ 156.9, 156.6, 131.0, 129.1, 122.9, 114.3, 109.4, 55.7. **HRMS** (ESI) found [M+H]⁺ 220.0728, C₁₀H₁₀N₃O₃ requires 220.0722.

(E)-2-(benzylamino)-N-hydroxy-2-oxoacetimidoyl cyanide (3i)




Subjection of **S1i** (1.63 g, 9.33 mmol) to General Procedure A gave the title compound (0.764 g, 3.76 mmol, 40 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 14.49 (s, 1H), 9.08 (t, *J* = 5.8 Hz, 1H), 7.34-7.24 (m, 5H), 4.39 (d, *J* = 6.2 Hz, 2H). **¹³C NMR** (126 MHz, DMSO) δ 158.6, 139.1, 128.8, 128.6, 127.7, 127.4, 109.4, 42.9. **HRMS** (ESI) found [M+H]⁺ 204.0773, C₁₀H₁₀N₃O₂ requires 204.0773.

(Z)-N-hydroxybenzimidoyl cyanide (3j)




Subjection of **S1j** (1.0 g, 8.54 mmol) to General Procedure B gave the title compound (0.777 g, 5.20 mmol, 61 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 13.77 (s, 1H), 7.76 – 7.69 (m, 2H), 7.56 – 7.49 (m, 3H). **¹³C NMR** (126 MHz, DMSO) δ 131.6, 131.3, 130.0, 129.7, 126.0, 110.6. **HRMS** (ESI) found [M+H]⁺ 147.0567, C₈H₇N₂O requires 147.0558.

(Z)-N-hydroxy-4-(trifluoromethyl)benzimidoyl cyanide (3k)




Subjection of **S1k** (1.0 g, 5.40 mmol) to General Procedure B gave the title compound (0.949 g, 4.32 mmol, 80 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc). $^1\text{H NMR}$ (500 MHz, DMSO- d_6) δ 14.16 (s, 1H), 7.93 (d, J = 8.3 Hz, 2H), 7.87 (d, J = 8.4 Hz, 2H). $^{13}\text{C NMR}$ (126 MHz, DMSO) δ 133.9, 131.0 (q, J = 32.3 Hz), 130.7, 130.2, 126.8, 126.6 (q, J = 3.8 Hz), 124.3 (q, J = 272.8 Hz). **HRMS** (ESI) found $[\text{M-H}]^-$ 213.0266, $\text{C}_9\text{H}_4\text{FN}_2\text{O}$ requires 213.0276.

(Z)-4-chloro-N-hydroxybenzimidoyl cyanide (3l)




Subjection of **S1l** (1.0 g, 6.60 mmol) to General Procedure B gave the title compound (1.03 g, 4.83 mmol, 73 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc). $^1\text{H NMR}$ (500 MHz, DMSO- d_6) δ 13.90 (s, 1H), 7.73 (d, J = 8.7 Hz, 2H), 7.58 (d, J = 8.7 Hz, 2H). $^{13}\text{C NMR}$ (126 MHz, DMSO) δ 135.9, 130.8, 129.8, 128.9, 127.7, 110.3. **HRMS** (ESI) found $[\text{M-H}]^-$ 178.9987, $\text{C}_8\text{H}_4\text{ClN}_2\text{O}$ requires 179.0012.

(E)-N-hydroxy-2-oxo-2-phenylacetimidoyl cyanide (3n)




Subjection of **S1n** (1.0 g, 6.89 mmol) to General Procedure A gave the title compound (1.13 g, 6.49 mmol, 94 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). $^1\text{H NMR}$ (500 MHz, DMSO- d_6) δ 15.06 (s, 1H), 7.92 (d, J = 7.2 Hz, 2H), 7.68 (t, J = 7.4 Hz, 1H), 7.54 (app t, J = 7.8 Hz, 2H). $^{13}\text{C NMR}$ (126 MHz, DMSO) δ 186.0, 135.2, 134.0, 133.6, 130.7, 128.7, 109.5. **HRMS** (ESI) found $[\text{M-H}]^-$ 173.0320, $\text{C}_9\text{H}_5\text{N}_2\text{O}_2$ requires 173.0351.

benzyl (E)-(2-cyano-2-(hydroxyimino)acetyl)phenylalaninate (3o)




Subjection of **S1o** (1.61 g, 5.0 mmol) to General Procedure A gave the title compound (0.829 g, 2.36 mmol, 47 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:2). **¹H NMR** (400 MHz, DMSO-*d*₆) δ 8.89 (d, *J* = 8.0 Hz, 1H), 7.41 – 7.29 (m, 5H), 7.29 – 7.18 (m, 5H), 5.15 (s, 2H), 4.68 (ddd, *J* = 9.5, 8.1, 5.5 Hz, 1H), 3.22 – 3.02 (m, 2H). **¹³C NMR** (126 MHz, DMSO) δ 171.0, 158.8, 137.6, 136.2, 129.6, 128.9, 128.7, 128.6, 128.3, 127.9, 127.1, 109.1, 66.8, 54.5, 36.2. **HRMS** (ESI) found [M+H]⁺ 352.1290, C₁₉H₁₈N₃O₄ requires 352.1297.

methyl (E)-4-(2-cyano-2-(hydroxyimino)acetamido)benzoate (3p)



Subjection of **S1p** (1.45 g, 6.62 mmol) to General Procedure A gave the title compound (0.911 g, 3.69 mmol, 56 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (1:1). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 14.74 (s, 1H), 10.73 (s, 1H), 7.96 (d, *J* = 8.8 Hz, 2H), 7.87 (d, *J* = 8.9 Hz, 2H), 3.84 (s, 3H). **¹³C NMR** (126 MHz, DMSO) δ 166.2, 157.8, 142.5, 130.6, 129.0, 125.6, 120.6, 109.2, 52.4. **HRMS** (ESI) found [M+H]⁺ 248.0668, C₁₁H₁₀N₃O₄ requires 248.0671.


(1E,2E)-1,2-bis(4-chlorophenyl)ethane-1,2-dione dioxime (3q)



A 20-mL vial equipped with a magnetic stir bar was charged with diketone **S1q** (1.0 g, 3.58 mmol), hydroxylamine hydrochloride (1.99 g, 28.7 mmol, 8.0 eq), and pyridine (6 mL). The solution was heated at 100 °C for 72 h at which point UPLC indicated complete consumption of the starting material. The reaction mixture was cooled to rt and diluted with ice cold water and neutralized with 1 N HCl. The aqueous layer was extracted with EtOAc (x2). The combined organics were washed with brine (x1), dried (Na₂SO₄) and concentrated to afford the title compound (0.861 g, 2.79 mmol, 78 % yield) as a white solid. **¹H NMR** (500 MHz, DMSO-*d*₆) δ

11.70 (s, 2H), 7.48 (app q, $J = 8.8$ Hz, 8H). ^{13}C NMR (126 MHz, DMSO) δ 149.95, 134.4, 132.0, 129.4, 127.7. HRMS (ESI) found $[\text{M}+\text{H}]^+$ 309.0200, $\text{C}_{14}\text{H}_{11}\text{Cl}_2\text{N}_2\text{O}_2$ requires 309.0197.

(2E,3Z)-3-amino-2,3-bis(hydroxyimino)-N-phenylpropanamide



A 20-mL vial equipped with a magnetic stir bar was charged with cyano-oxime **2a** (0.500 g, 2.64 mmol) and THF (10 mL). To the resulting homogeneous solution was added 50 wt % aqueous hydroxylamine (0.227 mg, 3.44 mmol) and the mixture was heated at 50 °C. Upon complete consumption of the starting material, as determined by UPLC analysis, the reaction mixture was cooled to room temperature and diluted with H_2O (10 mL). The aqueous layer was extracted with IPAC (x2). The combined organics were washed with brine (x1), dried (Na_2SO_4) and concentrated *in vacuo*. The crude residue was purified by column chromatography on silica gel using DCM/MeOH as eluent (100 % DCM to 20:1 DCM/MeOH) to afford the title compound (0.423 g, 1.90 mmol, 72 % yield) as a pale yellow solid. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 11.69 (s, 1H), 10.33 (s, 1H), 10.32 (s, 1H) 7.64 (d, $J = 7.7$ Hz, 2H), 7.30 (app tt, $J = 7.9$ Hz, 2H), 7.06 (t, $J = 7.4$ Hz, 1H), 5.37 (s, 2H). ^{13}C NMR (126 MHz, DMSO) δ 160.7, 148.4, 147.4, 139.3, 129.1, 123.8, 119.4. HRMS (ESI) found $[\text{M}+\text{H}]^+$ 221.0669, $\text{C}_9\text{H}_{11}\text{N}_4\text{O}_3$ requires 221.0675.


Synthesis of Furazans

General Procedure C: A 2-dram vial equipped with a magnetic stir bar was charged with the appropriate cyano-oxime (1.5 mmol, 1.0 eq.) and THF (5.6 mL, 0.25 M). To the resulting homogeneous solution was added 50 % aqueous hydroxylamine (0.129 g, 1.95 mmol, 1.3 eq.). The mixture was heated at 35 °C until UPLC analysis indicated complete consumption of the starting material (typically 12-16 h). The reaction mixture was cooled to rt and 1,1'-carbonyldiimidazole (0.365 g, 2.25 mmol, 1.5 eq.) was added portionwise. Upon cessation of gas evolution, the reaction mixture was sampled and typically judged to be complete by UPLC analysis. The reaction mixture was concentrated *in vacuo* and purified directly by column chromatography on silica gel using Hexs/EtOAc as eluent.

General Procedure D: A 2-dram vial equipped with a magnetic stir bar was charged with the appropriate cyano-oxime (1.5 mmol, 1.0 eq) and MeOH (5.6 mL, 0.25 M). To the resulting homogeneous solution was added 50 % aqueous hydroxylamine (0.198 g, 3.0 mmol, 2.0 eq.). The mixture was heated at 40 °C until UPLC analysis indicated complete consumption of the starting material (typically 12 h). The reaction mixture was cooled to rt, transferred to a 20-mL vial and concentrated *in vacuo* to remove methanol. The crude residue was concentrated two additional times with CH_2Cl_2 until a white solid was obtained. The white solid was dissolved in


THF (5.6 mL, 0.25 M) and CDI (0.365 g, 2.25 mmol, 1.5 eq.) was added, the vial was capped and the mixture stirred at room temperature. Upon complete consumption of the intermediate *bis*-oxime, as judged by UPLC analysis (typically 30 min), the reaction mixture was concentrated and purified directly by column chromatography on silica gel using Hexs/EtOAc as eluent.

4-amino-N-phenyl-1,2,5-oxadiazole-3-carboxamide (2a)




Subjection of cyano-oxime **3a** (2.0 g, 9.32 mmol) to General Procedure C gave the title compound (1.71 g, 8.38 mmol, 90 % yield). Note: rather than subjecting crude product to chromatography, the residue was taken up in EtOAc and washed with 1 N HCl (x1), H₂O (x1), brine (x1). The organic layer was dried (Na₂SO₄) and concentrated to afford spectroscopically pure material. ¹H NMR (500 MHz, DMSO-*d*₆) δ 10.96 (s, 1H), 7.77 (d, *J* = 7.9 Hz, 2H), 7.38 (app t, *J* = 7.7 Hz, 2H), 7.17 (t, *J* = 7.3 Hz, 1H), 6.44 (s, 2H). ¹³C NMR (126 MHz, DMSO) δ 157.0, 156.6, 141.5, 138.1, 129.2, 125.1, 121.2. HRMS (ESI) found [M+H]⁺ 205.0713, C₉H₉N₄O₂ requires 205.0726.

(4-amino-1,2,5-oxadiazol-3-yl)(pyrrolidin-1-yl)methanone (2b)



Subjection of cyano-oxime **3b** (0.251 g, 1.50 mmol) to General Procedure C gave the title compound (0.257 g, 1.41 mmol, 94 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). ¹H NMR (500 MHz, DMSO-*d*₆) δ 6.39 (s, 2H), 3.73 (t, *J* = 6.7 Hz, 2H), 3.52 (t, *J* = 6.8 Hz, 2H), 1.95 – 1.91 (m, 2H), 1.89 – 1.84 (m, 2H). ¹³C NMR (126 MHz, DMSO) δ 157.3, 157.1, 141.6, 48.7, 47.0, 26.1, 23.9. HRMS (ESI) found [M+H]⁺ 183.0886, C₇H₁₁N₄O₂ requires 183.0882.


(4-amino-1,2,5-oxadiazol-3-yl)(piperidin-1-yl)methanone (2c)



Subjection of cyano-oxime **3c** (0.272 g, 1.50 mmol) to General Procedure C gave the title compound (0.204 g, 1.04 mmol, 69 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). ¹H NMR (500 MHz, DMSO-*d*₆) δ 6.33 (s,


2H), 3.70 – 3.57 (m, 2H), 3.57 – 3.45 (m, 2H), 1.70 – 1.61 (m, 2H), 1.61 – 1.47 (m, 4H). ^{13}C NMR (126 MHz, DMSO) δ 157.1, 156.3, 142.3, 47.9, 43.1, 26.6, 25.5, 24.2. HRMS (ESI) found $[\text{M}+\text{H}]^+$ 197.1042, $\text{C}_8\text{H}_{13}\text{N}_4\text{O}_2$ requires 197.1039.

(4-amino-1,2,5-oxadiazol-3-yl)(morpholino)methanone (2d)




Subjection of cyano-oxime **3d** (0.275 g, 1.50 mmol) to General Procedure C gave the title compound (0.182 g, 0.92 mmol, 61 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). ^1H NMR (500 MHz, DMSO- d_6) δ 6.37 (s, 2H), 3.78 – 3.56 (m, 8H). ^{13}C NMR (126 MHz, DMSO) δ 157.6, 156.5, 141.8, 66.6, 66.2, 47.4, 42.71. HRMS (ESI) found $[\text{M}+\text{H}]^+$ 199.0825, $\text{C}_7\text{H}_{11}\text{N}_4\text{O}_3$ requires 199.0831.

4-amino-N-(4-chlorophenyl)-1,2,5-oxadiazole-3-carboxamide (2e)



Subjection of cyano-oxime **3e** (0.313 g, 1.40 mmol) to General Procedure C gave the title compound (0.288 g, 1.21 mmol, 86 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). ^1H NMR (500 MHz, DMSO- d_6) δ 11.10 (s, 1H), 7.81 (d, J = 8.9 Hz, 2H), 7.45 (d, J = 8.9 Hz, 2H), 6.44 (s, 2H). ^{13}C NMR (126 MHz, DMSO) δ 157.1, 156.6, 141.4, 137.1, 129.2, 128.9, 122.7. HRMS (ESI) found $[\text{M}-\text{H}]^-$ 237.0176, $\text{C}_9\text{H}_6\text{ClN}_4\text{O}_2$ requires 237.0180.


4-amino-N-(4-fluorophenyl)-1,2,5-oxadiazole-3-carboxamide (2f)



Subjection of cyano-oxime **3f** (0.200 g, 0.97 mmol) to General Procedure C gave the title compound (0.200 g, 0.90 mmol, 93 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs: EtOAc). ^1H NMR (500 MHz, DMSO- d_6) δ 11.03 (s, 1H), 7.81 – 7.77 (m, 2H), 7.30 – 7.06 (m, 2H), 6.43 (s, 2H). ^{13}C NMR (126 MHz, DMSO) δ 159.3 (d, J = 241.9 Hz), 156.96, 156.62, 141.41, 134.5 (d, J = 2.6 Hz),


134.47, 123.17, 123.11, 115.9 (d, $J = 22.4$ Hz). ^{19}F NMR (471 MHz, DMSO) δ -117.5. HRMS (ESI) found $[\text{M-H}]^-$ 221.0480, $\text{C}_9\text{H}_6\text{FN}_4\text{O}_2$ requires 221.0475.

4-amino-N-(4-(trifluoromethyl)phenyl)-1,2,5-oxadiazole-3-carboxamide (2g)




Subjection of cyano-oxime **3g** (0.386 g, 1.50 mmol) to General Procedure C gave the title compound (0.386 g, 1.42 mmol, 95 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs: EtOAc). ^1H NMR (500 MHz, DMSO- d_6) δ 11.31 (s, 1H), 8.01 (d, $J = 8.5$ Hz, 2H), 7.76 (d, $J = 8.6$ Hz, 2H), 6.47 (s, 2H). ^{13}C NMR (126 MHz, DMSO) δ 157.53, 156.65, 141.82, 141.37, 126.5 (d, $J = 3.8$ Hz), 125.1 (q, $J = 32.1$ Hz), 124.70 (q, $J = 271.9$), 121.1. ^{19}F NMR (471 MHz, DMSO) δ -60.5. HRMS (ESI) found $[\text{M-H}]^-$ 221.0447, $\text{C}_{10}\text{H}_6\text{F}_3\text{N}_4\text{O}_2$ requires 221.0443.

4-amino-N-(4-methoxyphenyl)-1,2,5-oxadiazole-3-carboxamide (2h)



Subjection of cyano-oxime **3h** (0.268 g, 1.22 mmol) to General Procedure C gave the title compound (0.237 g, 1.01 mmol, 83 % yield) as an orange solid after column chromatography on silica gel using Hexs/EtOAc as eluent (4:1 to 1:1). ^1H NMR (500 MHz, DMSO- d_6) δ 10.84 (s, 1H), 7.68 (d, $J = 9.1$ Hz, 2H), 6.95 (d, $J = 9.1$ Hz, 2H), 6.41 (s, 2H), 3.76 (s, 3H). ^{13}C NMR (126 MHz, DMSO) δ 156.7, 156.6, 156.6, 141.5, 131.1, 122.8, 114.3, 55.7. HRMS (ESI) found $[\text{M-H}]^-$ 233.0678, $\text{C}_{10}\text{H}_9\text{N}_4\text{O}_3$ requires 233.0675.


4-amino-N-benzyl-1,2,5-oxadiazole-3-carboxamide (2i)



Subjection of cyano-oxime **3i** (0.305 g, 1.50 mmol) to General Procedure C gave the title compound (0.234 g, 1.07 mmol, 72 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc). ^1H NMR (500 MHz, DMSO- d_6) δ 9.62 (t, $J = 5.9$ Hz, 1H), 7.38 – 7.31 (m, 4H), 7.29 – 7.23 (m, 1H), 6.36 (s, 2H),


4.46 (d, $J = 6.2$ Hz, 2H). ^{13}C NMR (126 MHz, DMSO) δ 158.5, 156.6, 140.9, 139.1, 128.8, 127.8, 127.5, 42.8. HRMS (ESI) found $[\text{M}+\text{H}]^+$ 219.0882, $\text{C}_{10}\text{H}_{11}\text{N}_4\text{O}_2$ requires 219.0882.

4-phenyl-1,2,5-oxadiazol-3-amine (2j)




Subjection of cyano-oxime **3j** (0.224 g, 1.50 mmol) to General Procedure D gave the title compound (0.171 g, 1.06 mmol, 71 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (9:1 to 3:2). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.84 – 7.71 (m, 2H), 7.64 – 7.50 (m, 3H), 6.21 (s, 2H). ^{13}C NMR (126 MHz, DMSO) δ 155.8, 147.3, 130.8, 129.6, 128.2, 126.0. HRMS (ESI) found $[\text{M}-\text{H}]^-$ 160.0483, $\text{C}_8\text{H}_6\text{N}_3\text{O}$ requires 160.0511.

4-(4-(trifluoromethyl)phenyl)-1,2,5-oxadiazol-3-amine (2k)




Subjection of cyano-oxime **3k** (0.329 g, 1.50 mmol) to General Procedure D gave the title compound (0.263 g, 1.15 mmol, 77 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (9:1 to 3:2). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.00 (d, $J = 8.0$ Hz, 2H), 7.93 (d, $J = 8.1$ Hz, 2H), 6.32 (s, 2H). ^{13}C NMR (126 MHz, DMSO) δ 155.8, 146.5, 130.8 (q, $J = 32.1$ Hz), 130.1, 129.2, 126.4 (q, $J = 3.8$ Hz), 124.4 (q, $J = 272.8$ Hz). ^{19}F NMR (471 MHz, DMSO) δ -61.5. HRMS (ESI) found $[\text{M}-\text{H}]^-$ 228.0357, $\text{C}_9\text{H}_5\text{F}_3\text{N}_3\text{O}$ requires 228.0385.

4-(4-chlorophenyl)-1,2,5-oxadiazol-3-amine (2l)




Subjection of cyano-oxime **3l** (0.271 g, 1.50 mmol) to General Procedure D gave the title compound (0.240 g, 1.23 mmol, 82 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (9:1 to 3:2). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.79 (d, $J = 8.6$ Hz, 2H), 7.63 (d, $J = 8.6$ Hz, 2H), 6.24 (s, 2H). ^{13}C NMR (126 MHz, DMSO) δ 155.7, 146.6, 135.6, 130.1, 129.7, 124.9. HRMS (ESI) found $[\text{M}-\text{H}]^-$ 194.0095, $\text{C}_8\text{H}_5\text{ClN}_3\text{O}$ requires 194.0121.

4-(pyridin-3-yl)-1,2,5-oxadiazol-3-amine (2m)




Subjection of cyano-oxime **3m** (0.221 g, 1.50 mmol) to General Procedure D gave the title compound (0.102 g, 0.63 mmol, 42 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (2:3 Hexs/EtOAc to 100 % EtOAc). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 8.95 (s, 1H), 8.75 (d, *J* = 3.8 Hz, 1H), 8.17 (d, *J* = 7.9 Hz, 1H), 7.60 (dd, *J* = 7.8, 4.9 Hz, 1H), 6.34 (s, 2H). **¹³C NMR** (126 MHz, DMSO) δ 155.9, 151.5, 148.6, 145.5, 136.0, 124.5, 122.5. **HRMS** (ESI) found [*M*+*H*]⁺ 163.0628, C₇H₇N₄O requires 163.0620.

(4-amino-1,2,5-oxadiazol-3-yl)(phenyl)methanone (2n)



Subjection of cyano-oxime **3n** (0.261 g, 1.50 mmol) to General Procedure C gave the title compound (0.157 g, 0.83 mmol, 55 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 8.17 (d, *J* = 7.6 Hz, 2H), 7.76 (t, *J* = 7.4 Hz, 1H), 7.62 (app t, *J* = 7.7 Hz, 2H), 6.61 (s, 2H). **¹³C NMR** (126 MHz, DMSO) δ 185.5, 157.3, 143.8, 136.1, 134.9, 130.5, 129.3. **HRMS** (ESI) found [*M*+*H*]⁺ 190.0624, C₉H₇N₃O₂ requires 190.0616.


benzyl (4-amino-1,2,5-oxadiazole-3-carbonyl)phenylalaninate (2o)



Subjection of cyano-oxime **3o** (0.527 g, 1.50 mmol) to General Procedure C gave the title compound (0.463 g, 1.26 mmol, 84 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 3:1 Hexs/EtOAc). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 9.55 (d, *J* = 7.5 Hz, 1H), 7.48 – 7.08 (m, 10H), 6.32 (s, 2H), 5.18 – 5.13 (m, 2H),


4.81 – 4.70 (m, 1H), 3.26 – 3.10 (m, 2H). ^{13}C NMR (126 MHz, DMSO) δ 171.0, 158.6, 156.5, 140.3, 137.7, 136.2, 129.5, 128.9, 128.8, 128.5, 128.3, 127.1, 66.8, 54.4, 36.2. HRMS (ESI) found $[\text{M}-\text{H}]^-$ 365.1272, $\text{C}_{19}\text{H}_{17}\text{N}_4\text{O}_4$ requires 365.1250.

methyl 4-(4-amino-1,2,5-oxadiazole-3-carboxamido)benzoate (2p)



Subjection of cyano-oxime **3p** (0.062 g, 0.25 mmol) to General Procedure C gave the title compound (0.047 g, 0.221 mmol, 72 % yield) as a white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc). ^1H NMR (500 MHz, DMSO- d_6) δ 11.28 (s, 1H), 7.98 (d, J = 8.7 Hz, 2H), 7.94 (d, J = 8.6 Hz, 2H), 6.46 (s, 2H), 3.85 (s, 3H). ^{13}C NMR (126 MHz, DMSO) δ 166.2, 157.4, 156.6, 142.6, 141.4, 130.6, 125.8, 120.6, 52.5. HRMS (ESI) found $[\text{M}-\text{H}]^-$ 261.0639, $\text{C}_{11}\text{H}_9\text{N}_4\text{O}_4$ requires 261.0624.

3,4-bis(4-chlorophenyl)-1,2,5-oxadiazole (2q)




A 2-dram vial equipped with a magnetic stir bar was charged with **3q** (0.231 g, 0.75 mmol) and DMF (5.8 mL). To the homogeneous solution was added 1,1'-carbonyldiimidazole (0.242 mg, 1.5 mmol). The vial was sealed and heated at 80 C for 16 h, at which point the mixture was cooled to rt and diluted with EtOAc and H_2O . The layers were separated and the aqueous layer extracted with EtOAc (x2). The combined organics were washed with H_2O (x3), dried (Na_2SO_4) and concentrated *in vacuo*. The crude residue was purified by column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc) to afford the title compound (0.122 g, 0.419 mmol, 56 % yield) as a white solid. ^1H NMR (500 MHz, DMSO- d_6) δ 7.62 (d, J = 8.5 Hz, 4H), 7.56 (d, J = 8.5 Hz, 4H). ^{13}C NMR (126 MHz, DMSO) δ 153.0, 136.2, 131.2, 129.8, 124.3. HRMS (ESI) found $[\text{M}+\text{H}]^+$ 291.0147, $\text{C}_{14}\text{H}_8\text{Cl}_2\text{N}_2\text{O}$ requires 261.0624.

Furazan Derivatization

General Procedure E: A 40-mL vial equipped with a magnetic stir bar was charged with the appropriate amino-furazan (1.0 mmol, 1.0 eq.), MeCN (4.5 mL), AcOH (4.5 mL), concentrated HCl (2.46 mL, 30 eq.) and lithium chloride (0.127 g, 3.0 mmol, 3.0 eq.) resulting in a nearly


homogeneous solution. The mixture was cooled to 0 °C using an ice water bath. In a separate 1-dram vial, sodium nitrite (0.103 g, 1.5 mmol, 1.5 eq.) was dissolved in minimal H₂O (0.2 mL). The solution was added dropwise to the reaction mixture at 0 °C, resulting in a color change from colorless to yellow. After 10 min of vigorous stirring at 0 °C, the reaction mixture was allowed to warm to room temperature. Upon complete consumption of the starting material, as judged by UPLC analysis (typically 30 min), the reaction mixture was diluted with sat. aq. NH₄Cl, resulting in a white precipitate. The contents of the vial were transferred to a separatory funnel and partitioned between EtOAc and H₂O. The aqueous layer was extracted with EtOAc (x3). The combined organics were dried (Na₂SO₄) and concentrated *in vacuo*. The resulting crude residue was purified by column chromatography on silica gel using Hexs/EtOAc as eluent.

4-chloro-N-phenyl-1,2,5-oxadiazole-3-carboxamide (4a)




Subjection of **2a** (0.500 g, 2.32 mmol) to General Procedure E afforded the title compound (0.465 g, 2.08 mmol, 90 % yield) as an off-white solid after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 11.19 (s, 1H), 7.75 (d, *J* = 8.1 Hz, 2H), 7.41 (app t, *J* = 7.8 Hz, 2H), 7.20 (t, *J* = 7.3 Hz, 1H). **¹³C NMR** (126 MHz, DMSO) δ 153.7, 148.7, 146.6, 137.9, 129.4, 125.5, 121.0. **HRMS** (ESI) found [M-H]⁺ 222.0050, C₉H₅ClN₃O₂ requires 222.0071.

N-benzyl-4-chloro-1,2,5-oxadiazole-3-carboxamide (4i)




Subjection of **2i** (0.218 g, 1.00 mmol) to General Procedure E afforded the title compound (0.177 g, 0.75 mmol, 75 % yield) as a colorless oil after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 9.77 (s, 1H), 7.38 – 7.33 (m, 4H), 7.32 – 7.25 (m, 1H), 4.50 (d, *J* = 6.1 Hz, 2H). **¹³C NMR** (126 MHz, DMSO) δ 155.3, 148.5, 146.4, 138.5, 128.9, 127.9, 127.6, 43.1. **HRMS** (ESI) found [M-H]⁺ 236.0227, C₁₀H₇ClN₃O₂ requires 236.0227.

3-chloro-4-(p-trifluoromethyl)-1,2,5-oxadiazole (4k)




Subjection of **2k** (0.229 g, 1.00 mmol) to General Procedure E afforded the title compound (0.185 g, 0.74 mmol, 74 % yield) as a pale yellow oil after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 8.13 (d, *J* = 8.2 Hz, 2H), 8.01 (d, *J* = 8.3 Hz, 2H). **¹³C NMR** (126 MHz, DMSO) δ 152.2, 146.2, 131.9 (q, *J* = 32.3 Hz), 129.8, 127.8, 126.6 (q, *J* = 3.8 Hz), 124.2 (q, *J* = 273.0 Hz). **¹⁹F NMR** (471 MHz, DMSO) δ -61.7. **HRMS** (ESI) found [*M*-Cl]⁻ 213.0275, C₉H₄F₃N₂O requires 222.0071.

benzyl (4-chloro-1,2,5-oxadiazole-3-carbonyl)phenylalaninate (**4o**)



Subjection of **2o** (0.366 g, 1.00 mmol) to General Procedure E afforded the title compound (0.312 g, 0.81 mmol, 81 % yield) as a pale yellow oil after column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 9.78 (d, *J* = 7.7 Hz, 1H), 7.43 – 7.16 (m, 10H), 5.18 (d, *J* = 12.6 Hz, 1H), 5.15 (d, *J* = 12.6 Hz, 1H), 4.86 – 4.74 (m, 1H), 3.23 (dd, *J* = 13.9, 5.4 Hz, 1H), 3.11 (dd, *J* = 13.8, 9.7 Hz, 1H). **¹³C NMR** (126 MHz, DMSO) δ 170.6, 155.4, 148.2, 146.1, 137.2, 136.1, 129.6, 128.9, 128.8, 128.6, 128.3, 127.1, 66.9, 54.7, 36.4. **HRMS** (ESI) found [*M*+H]⁺ 386.0913, C₁₉H₁₇ClN₃O₄ requires 386.0908.


4-butoxy-N-phenyl-1,2,5-oxadiazole-3-carboxamide (**5a**)



A 2-dram vial equipped with a magnetic stir bar was charged with sodium hydride (60 wt % suspension in mineral oil, 0.240 g, 6.0 mmol, 6.0 eq.) and THF (1 mL). In a separate vial, *n*-butanol (0.111 g, 1.5 mmol, 1.5 eq.) was dissolved in THF (2.5 mL) and the resulting solution was added to the NaH suspension at room temperature. The mixture was stirred for 5 min at room temperature at which point **4a** (0.224 g, 1.0 mmol, 1.0 eq) was added as a solid. The mixture was heated at 50 °C for 75 min, at which point UPLC analysis indicated complete


consumption of **4a**. The reaction mixture was cooled to room temperature and quenched with 1 N HCl. The aqueous layer was extracted with EtOAc (x3). The combined organics were washed with brine (x1), dried (Na₂SO₄) and concentrated *in vacuo*. The crude residue was purified by column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc) to afford the title compound (0.231 g, 0.884 mmol, 88 % yield) as a colorless oil. **¹H NMR** (500 MHz, DMSO-*d*₆) δ 10.93 (s, 1H), 7.71 (d, *J* = 7.7 Hz, 2H), 7.40 (app t, *J* = 7.9 Hz, 2H), 7.18 (t, *J* = 7.4 Hz, 1H), 4.41 (t, *J* = 6.5 Hz, 2H), 1.82 – 1.74 (m, 2H), 1.48 – 1.39 (m, 2H), 0.93 (t, *J* = 7.4 Hz, 3H). **¹³C NMR** (126 MHz, DMSO) δ 163.8, 154.5, 143.0, 138.1, 129.4, 125.3, 120.7, 73.3, 30.6, 18.8, 14.0. **HRMS** (ESI) found [M+H]⁺ 262.1197, C₁₃H₁₆N₃O₃ requires 262.1192.

4-(dodecylthio)-N-phenyl-1,2,5-oxadiazole-3-carboxamide (**6a**)




A 2-dram vial equipped with a magnetic stir bar was charged with sodium hydride (60 wt % suspension in mineral oil, 0.240 g, 6.0 mmol, 6.0 eq.) and THF (3 mL). In a separate vial, *n*-dodecanethiol (0.304 g, 1.5 mmol, 1.5 eq.) was dissolved in THF (1.5 mL) and the resulting solution was added to the NaH suspension at room temperature. The mixture was stirred for 5 min at room temperature at which point **4a** (0.224 g, 1.0 mmol, 1.0 eq) was added as a solid. The mixture was heated at 50 °C for 75 min, at which point UPLC analysis indicated complete consumption of **4a**. The reaction mixture was cooled to room temperature and quenched with 1 N HCl. The aqueous layer was extracted with EtOAc (x3). The combined organics were washed with brine (x1), dried (Na₂SO₄) and concentrated *in vacuo*. The crude residue was purified by column chromatography on silica gel using Hexs/EtOAc as eluent (100 % Hexs to 4:1 Hexs/EtOAc) to afford the title compound (0.333 g, 0.855 mmol, 85 % yield) as a white solid. **¹H NMR** (400 MHz, DMSO-*d*₆) δ 11.09 (s, 1H), 7.75 (d, *J* = 7.6 Hz, 2H), 7.42 – 7.35 (m, 2H), 7.18 (t, *J* = 7.4 Hz, 1H), 3.18 (t, *J* = 7.3 Hz, 2H), 1.78 – 1.69 (m, 2H), 1.45 – 1.35 (m, 2H), 1.34 – 1.18 (m, 16H), 0.91 – 0.77 (m, 3H). **¹³C NMR** (126 MHz, DMSO) δ 155.1, 154.5, 148.7, 138.0, 129.3, 125.3, 121.1, 32.0, 31.8, 29.5, 29.5, 29.4, 29.3, 29.2, 28.9, 28.6, 28.5, 22.6, 14.4. **HRMS** (ESI) found [M-H]⁺ 388.2038, C₂₁H₃₀N₃O₂S requires 388.2059.

4-hydroxy-N-phenyl-1,2,5-oxadiazole-3-carboxamide (**8a**)



A 1-dram vial equipped with a magnetic stir bar was charged with **4a** (0.155 g, 0.69 mmol) and DMSO (2.3 mL). To the resulting homogeneous mixture were added N-hydroxyacetamide (0.156 g, 2.08 mmol) and potassium carbonate (0.479 g, 3.47 mmol) and the mixture was heated at 80 °C. Upon complete consumption of the starting material, as judged by UPLC analysis (60 min), the reaction mixture was cooled to room temperature and slowly quenched with 2 N HCl (3.11 mL, 6.24 mmol) until pH = ca. 3. The aqueous layer was extracted with EtOAc (x2). The combined organics were concentrated *in vacuo* and the crude residue was purified via column chromatography on silica gel using Hexs/EtOAc as eluent (1:1) to afford the title compound (0.104 g, 0.51 mmol, 73 % yield) as a white solid. **¹H NMR** (500 MHz, DMSO-*d*₆) δ 10.85 (s, 1H), 7.72 (d, *J* = 7.8 Hz, 2H), 7.39 (app t, *J* = 7.9 Hz, 2H), 7.17 (t, *J* = 7.4 Hz, 1H). **¹³C NMR** (126 MHz, DMSO) δ 162.5, 155.4, 143.8, 138.2, 129.4, 125.2, 120.6. **HRMS** (ESI) found [M-OH]⁺ 145.0402, C₈H₅N₂O requires 145.0402.



Chiral SFC Trace of 2o



Chiral SFC analysis was performed to demonstrate the lack of racemization during the preparation of furazan **2o**. This analysis was conducted using an OD-3 column (150 x 4.6 mm, 3 μ m) at 40 °C. Mobile phase A: CO₂, mobile phase B: 25 mM IBA in IPA (1-40 % MPB 0-5 min, 40 % MPB 5-6 min, 3 mL/min, 200 bar).

Differential Scanning Calorimetry Data


Differential scanning calorimetry measurements for compounds **3a**, **3j**, **1a**, **1q**, **2a**, **2j**, and **2q** were obtained using 5 °C/min scan rate up to 350 °C in a Tantalum coated cell.



Sample: NB 0403706-0058 Q1636
 Size: 4.1300 mg
 Method: Standard DSC method
 Comment: NB 03403706-0058

DSC


File: T:\...NB 0403706-0058.002
 Operator: SS
 Run Date: 02-Oct-2017 08:23
 Instrument: DSC Q200 V24.11 Build 124



Sample: NB 0403706-0064 Q1636
 Size: 3.8400 mg
 Method: Standard DSC method
 Comment: NB 0403706-0064

DSC


File: T:\...NB 0403706-0064.001
 Operator: JB
 Run Date: 26-Sep-2017 13:50
 Instrument: DSC Q200 V24.11 Build 124



Sample: NB 0403706-0077 Q1636
 Size: 3.5700 mg
 Method: Standard DSC method
 Comment: NB 03403706-0077

DSC


File: T:\...NB 0403706-0077.002
 Operator: SS
 Run Date: 02-Oct-2017 10:10
 Instrument: DSC Q200 V24.11 Build 124



Sample: NB 0403706-0019 Q1636
 Size: 3.9700 mg
 Method: Standard DSC method
 Comment: NB 0403706-0019

DSC


File: T:\...NB 0403706-0019.001
 Operator: JB
 Run Date: 27-Sep-2017 08:39
 Instrument: DSC Q200 V24.11 Build 124



Sample: NB 0403706-0090 Q1636
Size: 3.1000 mg
Method: Standard DSC method
Comment: NB 03403706-0090

DSC



File: T:\NB 0403706-0090.002
Operator: SS
Run Date: 29-Sep-2017 14:09
Instrument: DSC Q200 V24.11 Build 124




References

¹Sauerberg, P.; Olesen, P. H.; Neilsen, S.; Treppendahl, S.; Sheardown, M. J.; Honore, T.; Mitch, C. H.; Ward, J. S.; Pike, A. J.; Bymaster, F. P.; Sawyer, B. D.; Shannon, H. E. *J. Med. Chem.* **1992**, 35 (12), 2274.


0403706-0131_1H_DMSO.10.fid
rynmr500d h-1




0403706-0131_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0050.DMSO.10.fid
rynmr500d h-




0403706-0050_13C_DMSO.20.fid
rynmr500d c-13 (daytime queue)





0403706-0027_crude_DMSO.10.fid
rynmr500d h-1




0403706-0027_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)





0403706-0028_1H_DMSO.10.fid
rynmr500d h-1




0403706-0028_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0029_1H_DMSO.10.fid
rynmr500d h-1




0403706-0029_13C_DMSO.20.fid
rynmr500d c-13 (daytime queue)




0403706-0026.DMSO.10.fid
rynmr500d h-1




0403706-0026_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0039_purified_DMSO.10.fid
rynmr500d h-1H




0403706-0039_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0040_DMSO.10.fid
rynmr500d h1




0403706-0040_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0048_19F_DMSO_2.10.fid
rynmr500d f-19 (decoupled)




0403706-0038_1H_DMSO.10.fid
rynmr500d h-1




0403706-0038_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0041_1H_dmsd.10.fid
rynmr500d h-1




0403706-0041_13C_DMSO.20.fid
rynmr500d c-13 (daytime queue)





0403706-0130_1H_DMSO.10.fid
rynmr500d h-1




0403706-0130_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0129_1H_DMSO.10.fid
rynmr500c h




0403706-0129_13C_DMSO.10.fid
rynmr500c c-13 (daytime queue)





0403706-0128_1H_DMSO.10.fid
rynmr500c h-1




0403706-0128_13C_DMSO.10.fid
rynmr500c c-13 (daytime queue)





0403706-0012_13H_DMSO.10.fid
rynmr500c h-1




0403706-0012_13C_DMSO.10.fid
rynmr500c c-13 (8ytime queue)




0403706-0044_DMSO.10.fid
0403706-0044_DMSO/10 neelandr




0403706-0076_isolated_DMSO.10.fid
 rynnrmr500d h1




0403706-0076_13C_DMSO.20.fid
 rynnrmr500d c-13 (daytime queue)




0403706-0064_isolated_DMSO.10.fid
rynmr500d h-1




0403706-0064_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0058_1H_DMSO.10.fid
rynmr500d h-1




0403706-0058_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0031_1H_DMSO.10.fid
rynmr500d h-1




0403706-0031_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0032_1H_DMSO.10.fid
rynmr500d h-1




0403706-0032_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)





0403706-0033_1H_DMSO.10.fid
rynmr500d h-1




0403706-0033_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)





0403706-0045_DMSO.10.fid
rynmr500d h-1




0403706-0045_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0047_DMSO.10.fid
rynmr500d h-1




0403706-0047_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0047_19F_DMSO.10.fid
rynmr500d f-19 (decoupled)




0403706-0048_DMSO.10.fid
rynmr500d h-1




0403706-0048_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0048_19F_DMSO_2.10.fid
rynmr500d f-19 (decoupled)





0403706-0046_DMSO.10.fid
rynmr500d h-1




0403706-0046_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)




0403706-0049_DMSO.10.fid
rynmr500d h-1




0403706-0049_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)





0403706-0134_1H_DMSO.10.fid
rynmr500c h-1




0403706-0134_13C_DMSO.10.fid
rynmr500c c-13 (daytime queue)




0403706-0124_1H_DMSO.20.fid
rynmr500d h-1




0403706-0124_13C_DMSO.30.fid
rynmr500d c-13 (night, 5 hr, ns=10280)




0403706-0124_19F_DMSO.20.fid
rynmr500d f-19 (decoupled)




0403706-0132_1H_DMSO.10.fid
rynmr500c h-1




0403706-0132_13C_DMSO.10.fid
rynmr500c c-13 (daytime queue)





0403706-0137_1H_DMSO.10.fid
rynmr500d h-1





0403706-0137_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)








0403706-0051_purified_DMSO.10.fid
rynmr500d h-1





0403706-0051_purified_DMSO.10.fid
rynmr500d c-13 (daytime queue)






0403706-0092_1H_DMSO.10.fid
rynmr500d h-1



7.6246
7.6077
7.5717
7.5547




0403706-0092_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)

153.0335
136.2232
131.1663
129.7718
124.3126







0403706-0113_1H_DMSO.10.fid
rynmr500d h-1




0403706-0113_13C_DMSO.10.fid
rynmr500c c-13 (daytime queue)




0403706-0135_1H_DMSO.10.fid
rynmr500d h-1






0403706-0135_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)





0403706-0135_19F_DMSO.10.fid
rynmr500d f-19 (decoupled)











0403706-0126_fraction7_1H_DMSO.10.fid
rynmr500d h-1



0403706-0126_fraction7_13C_DMSO.10.fid
rynmr500d c-13 (daytime queue)

